NSE filing, NSE: EPIGRAL. Summary written from the filing by ALFA Finder's alert engine.
Epigral Ltd: key numbers
- Share price
- ₹943.95
- Market cap
- ₹4,072 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 14.3×Sector 34.8×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue up 28% and PAT up 26%, but EBITDA rose only 3% as margin fell to 18%. Management's FY27 outlook is qualitative; no growth number was given.
Epigral Investor Presentation: Key Takeaways
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral Results Update
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Epigral Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 27.1% YoY
Epigral Ltd reported revenue from operations of ₹746 Cr (+27.0% YoY) and net profit of ₹65.1 Cr (+27.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +27.1% YoY
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral Legal & Regulatory
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
- Value
- ₹28.11 Cr
Other price movement clarification announcements
All →Aerpace Industries Price Movement Clarification
Aerpace Industries clarified that recent significant movement in its share price is market-driven. The company confirmed it has no undisclosed material information impacting the stock price.
Sotac Pharmaceuticals Price Movement Clarification
Sotac Pharmaceuticals clarified that recent share price movements are entirely market-driven. The company confirmed it has disclosed all material information in compliance with SEBI regulations.
KRN Heat Exchanger and Refrigeration Price Movement Clarification
KRN Heat Exchanger and Refrigeration clarified that the recent significant increase in share trading volume is purely market-driven. The company confirmed no undisclosed price-sensitive information is pending.
Abram Food Price Movement Clarification
Abram Food Limited clarified that recent equity share price movements are purely market-driven. The company confirmed there is no undisclosed price-sensitive information or pending announcements.
Dhillon Freight Carrier Price Movement Clarification
Dhillon Freight Carrier Ltd clarified that recent share price movements are market-driven. The company confirmed no undisclosed material events or information exist that could affect its scrip behavior.
Innovision Price Movement Clarification
Innovision Ltd clarified that recent equity share price movements are market-driven with no undisclosed material information. The company confirmed full compliance with SEBI disclosure regulations.